James C. King

5.2k total citations · 1 hit paper
73 papers, 3.8k citations indexed

About

James C. King is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, James C. King has authored 73 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Epidemiology, 18 papers in Infectious Diseases and 10 papers in Microbiology. Recurrent topics in James C. King's work include Influenza Virus Research Studies (40 papers), Respiratory viral infections research (40 papers) and Pneumonia and Respiratory Infections (18 papers). James C. King is often cited by papers focused on Influenza Virus Research Studies (40 papers), Respiratory viral infections research (40 papers) and Pneumonia and Respiratory Infections (18 papers). James C. King collaborates with scholars based in United States, United Kingdom and Australia. James C. King's co-authors include Robert B. Belshe, Pedro A. Piedra, Mark Wolff, William C. Gruber, Karen Kotloff, David I. Bernstein, Paul M. Mendelman, Ken Zangwill, Frederick G. Hayden and John J. Treanor and has published in prestigious journals such as New England Journal of Medicine, JAMA and PLoS ONE.

In The Last Decade

James C. King

73 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

1998 697 citations Robert B. Belshe, John J. Treanor et al. profile →

Peers

Countries citing papers authored by James C. King

Since Specialization

Citations

This map shows the geographic impact of James C. King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James C. King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James C. King more than expected).

Fields of papers citing papers by James C. King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James C. King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James C. King. The network helps show where James C. King may publish in the future.

Co-authorship network of co-authors of James C. King

This figure shows the co-authorship network connecting the top 25 collaborators of James C. King. A scholar is included among the top collaborators of James C. King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James C. King. James C. King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents 2015 ·Vaccine ·James C. King, Yonghong Gao, Conrad P. Quinn, Thomas M. Dreier, (unknown), Eric M. Espeland	6
2	Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children 2014 ·The Pediatric Infectious Disease Journal ·Karen L. Kotloff, Natasha Halasa, Christopher J Harrison, Janet A. Englund, Emmanuel B. Walter, James C. King, C. Buddy Creech, Sara A. Healy, Rowena J Dolor, (unknown), Kathryn M. Edwards, Diana L. Noah, Heather Hill, Mark Wolff	8
3	Surge in Hospitalizations Associated With Mechanical Ventilator Use During Influenza Outbreaks 2014 ·Disaster Medicine and Public Health Preparedness ·James C. King, Adebola Ajao, Richard Lichenstein, Laurence S. Magder	9
4	Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. November 13, 2012 2012 ·Vaccine ·James C. King, Richard Lichenstein, Laurence S. Magder	8
5	The Relationship Between Influenza Outbreaks and Acute Ischemic Heart Disease in Maryland Residents Over a 7-Year Period 2012 ·The Journal of Infectious Diseases ·Richard Lichenstein, Laurence S. Magder, (unknown), James C. King	22
6	Impact of influenza vaccination of schoolchildren on medical outcomes among all residents of Maryland 2010 ·Vaccine ·James C. King, Richard Lichenstein, Ginny E. Cummings, Laurence S. Magder	29
7	Evaluation of a Computer-based Patient Education and Motivation Tool on Knowledge, Attitudes and Practice towards Influenza Vaccination 2009 ·Ashish Joshi, Richard Lichenstein, James C. King, Mohit Arora, Salwa Khan	11
8	The Interferon Antagonist NS2 Protein of Respiratory Syncytial Virus Is an Important Virulence Determinant for Humans 2006 ·The Journal of Infectious Diseases ·Peter F. Wright, Ruth A. Karron, Shabir A. Madhi, John J. Treanor, James C. King, (unknown), Mine R. Ikizler, Yuwei Zhu, Peter L. Collins, Clare Cutland, Valerie B. Randolph, Anne M. Deatly, Jill Hackell, William C. Gruber, Brian R. Murphy	78
9	Influence of prenatal diagnosis and pregnancy termination of fetuses with birth defects on the perinatal mortality rate in Victoria, Australia 2005 ·Paediatric and Perinatal Epidemiology ·Natasha Davidson, Jane Halliday, Merilyn Riley, James C. King	15
10	Dosage Escalation, Safety and Immunogenicity Study of Four Dosages of a Tetravalent Meninogococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Infants 2004 ·The Pediatric Infectious Disease Journal ·Margaret B. Rennels, James C. King, Robert Ryall, Thomas Papa, James E. Froeschle	80
11	Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults 2002 ·The Journal of Infectious Diseases ·James Campbell, Robert Edelman, James C. King, Thomas Papa, Robert Ryall, (unknown)	64
12	Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children 2001 ·The Pediatric Infectious Disease Journal ·James C. King, Patricia Fast, Kenneth M. Zangwill, Geoffrey A. Weinberg, Mark Wolff, Lihan Yan, (unknown), Robert B. Belshe, Andrea Kovacs, Jaime G. Deville, Marie T. Jelonek	67
13	Influenza Vaccines 2000 ·Pediatric Annals ·James C. King	1
14	Bacteremia in febrile human immunodeficiency virus-infected children presenting to ambulatory care settings 1998 ·The Pediatric Infectious Disease Journal ·Richard Lichenstein, James C. King, John Farley, (unknown), Prasanna Nair, Peter Vink	7
15	Evaluation of Live Attenuated Influenza Vaccines in Children 6-18 Months of Age: Safety, Immunogenicity, and Efficacy 1996 ·The Journal of Infectious Diseases ·William C. Gruber, Robert B. Belshe, James C. King, John J. Treanor, Pedro A. Piedra, Peter F. Wright, George Reed, Elizabeth M. Anderson, Frances K. Newman	71
16	Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children 1996 ·The Pediatric Infectious Disease Journal ·James C. King, Peter Vink, John Farley, (unknown), (unknown), Dace V. Madore, Richard Lichenstein, Frank Malinoski	69
17	Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection 1994 ·The Journal of Pediatrics ·John Farley, James C. King, Prasanna Nair, Susan E. Hines, Randall L. Tressler, Peter Vink	56
18	The A/Mallard/67S0/78 Avian-Human, but Not the A/Ann Arbor/6/60 Cold-Adapted, Influenza A/Kawasaki/86 (H1N1) Reassortant Virus Vaccine Retains Partial Virulence for Infants and Children 1991 ·The Journal of Infectious Diseases ·(unknown), N. A. Halsey, Louis Fries, Mark H. Wilson, James C. King, B. A. Burns, (unknown), (unknown), Brian R. Murphy, M L Clements	49
19	Safety and Immunogenicity of Human Rotavirus Vaccine Strain M37 in Adults, Children, and Infants 1991 ·The Journal of Infectious Diseases ·(unknown), N. A. Halsey, Mary Jett‐Goheen, M L Clements, M. C. Steinhoff, James C. King, Ruth A. Karron, (unknown), Bridget Burns, (unknown), (unknown), A Z Kapikian	21
20	Simultaneous Administration of Two Human-Rhesus Rotavirus Reassortant Strains of VP7 Serotype 1 and 2 Specificity to Infants and Young Children 1991 ·The Journal of Infectious Diseases ·Paul Wright, James C. King, Kazuko Araki, Yasuo Kondo, Jamie Thompson, Sharon J. Tollefson, Masaaki Kobayashi, A. Z. Kapikian	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact